EUVIMEDEUVIMED entdecken
Open Access

Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women

Stephanie S Maldonado, Marcelle I Cedars, Katherine P Yates, Laura A Wilson, Ryan Gill, Norah A Terrault, Ayako Suzuki, Monika A Sarkar

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2023.08.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Stephanie S Maldonado und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Polycystic Ovary Syndrome, Ovarian Reserve, Dyslipidemias. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Antimüllerian hormone (AMH) is a marker of ovarian reserve with emerging data linking lower levels to some metabolic and inflammatory diseases in women. Whether AMH levels influence nonalcoholic fatty liver disease (NAFLD) is unknown. METHODS: Leveraging the NASH Clinical Research Network we determined the association of AMH levels within 6 months of liver biopsy with presence and severity of histologic measures of NAFLD in premenopausal women. Outcomes included presence of nonalcoholic steatohepatitis (NASH), presence and severity of fibrosis, and NAFLD Activity Score and its components. Logistic and ordinal logistic regression models were adjusted for age, race/ethnicity, homeostatic model assessment for insulin resistance, body mass index, dyslipidemia, polycystic ovary syndrome, estrogen-progestin use, and menstrual cyclicity. RESULTS: Median cohort age was 35 years; 73% were white and 24% Hispanic. Thirty-three percent had diabetes, 81% had obesity, and 95% had dyslipidemia. On biopsy 71% had NASH, 68% had any fibrosis, and 15% had advanced fibrosis. On adjusted analysis (n = 205), higher AMH quartiles were inversely associated with NAFLD histology including prevalent NASH (adjusted odds ratio [AOR], 0.64; 95% confidence interval [CI], 0.41-1.00), NAFLD Activity Score ≥5 (AOR, 0.52; 95% CI, 0.35-0.77), Mallory hyaline (AOR, 0.54; 95% CI, 0.35-0.82), and higher fibrosis stage (AOR, 0.70; 95% CI, 0.51-0.98). The protective effects of AMH were more pronounced among women without polycystic ovary syndrome (n = 164), including lower odds of NASH (AOR, 0.53; 95% CI, 0.32-0.90) and any NASH fibrosis (AOR, 0.54; 95% CI, 0.32-0.93). CONCLUSIONS: AMH may reflect a unique biomarker of NASH in premenopausal women and findings suggest a novel link between reproductive aging and histologic severity of NAFLD in women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseasePolycystic Ovary SyndromeOvarian ReserveDyslipidemiasHumansFemaleAdultAnti-Mullerian HormoneLiver CirrhosisLiverBiopsy

Stichwörter der Autor:innen

Hepatic FibrosisNonalcoholic Fatty Liver DiseasePolycystic Ovary SyndromeReproductive AgingSex Hormones

Substanzen

Anti-Mullerian Hormone

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California.
  • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of California, San Francisco, San Francisco, California.
  • Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
  • Department of Pathology, University of California, San Francisco, San Francisco, California.
  • Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California.
  • Division of Gastroenterology, Duke University, Durham, North Carolina.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • GlaxoSmithKline
  • Liver Center, University of California, San Francisco
  • Office of the Director
  • Gilead Sciences

Zitieren

APA

Maldonado, S. S., Cedars, M. I., Yates, K. P., Wilson, L. A., Gill, R., Terrault, N. A., Suzuki, A., & Sarkar, M. A. (2024). Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.08.020

Vancouver

Maldonado SS, Cedars MI, Yates KP, Wilson LA, Gill R, Terrault NA, et al. Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.08.020

BibTeX
@article{Maldonado2024,
  author = {Maldonado, Stephanie S and Cedars, Marcelle I and Yates, Katherine P and Wilson, Laura A and Gill, Ryan and Terrault, Norah A and Suzuki, Ayako and Sarkar, Monika A},
  title = {Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2023.08.020}
}
Kostenlos starten →